AcrySof Single-Piece IOL (SA60AT); AcrySof IQ Aspheric IOL (SN60WF); AcrySof Aspheric UV-Absorbing IOL (SA60WF); AcrySof
Alcon Laboratories, Inc. · Decision date Apr 30, 2026
What did the FDA approve?
FDA records P930014/S161 as a supplement to PMA P930014, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Apr 30, 2026.
FDA approval order statement
approval application (PMA) 180-day supplement, which requested approval for a new packaging configuration, automation of the primary and secondary packaging processes, and updates to shelf-life and storage conditions of the AcrySof IOLs (storage condition temperatures from 45 °C to 30 °C), and Clareon IOLs (to extend the shelf life from four (4) years to five (5) years at the temperature of 30 °C) in Alcons manufacturing facilities in West Virginia, USA and Cork, Ireland.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Ophthalmic
- Decision date
- Apr 30, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P930014/S161
- Regulatory pathway
- PMA supplement
- Applicant
- Alcon Laboratories, Inc.
- Product code
- HQL
- Decision code
- APPR
- Decision date
- Apr 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Applicant
- Alcon Laboratories, Inc.
- Product code
- HQL
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P930014/S157 · Related supplement
AcrySof Posterior Chamber Intraocular Lens and Delivery Systems
P930014/S158 · Related supplement
AcrySof Posterior Chamber Intraocular Lens and Delivery Systems
P930014/S159 · Related supplement
AcrySof Posterior Chamber Intraocular Lens and Delivery Systems
P930014/S161 received
Application receipt date recorded by FDA.
P930014/S160 · Related supplement
AcrySof Posterior Chamber Intraocular Lens and Delivery Systems
P930014/S162 · Related supplement
AcrySof Posterior Chamber Intraocular Lens and Delivery Systems
P930014/S161 · FDA decision
Normal 180 Day Track
P930014/S165 · Related supplement
AcrySof Posterior Chamber Intraocular Lens and Delivery Systems
P930014/S163 · Related supplement
Acrosof Posterior Chamber Intraocular Lens
P930014/S164 · Related supplement
AcrySof Posterior Chamber Intraocular Lens and Delivery Systems
Timeline entries are records held by MedtechLedger for P930014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P930014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Laboratories, Inc. | PMA supplement | Aug 25, 2025 | FDA | |
| Alcon Laboratories, Inc. | PMA supplement | Sep 18, 2025 | FDA | |
| Alcon Laboratories, Inc. | PMA supplement | Dec 12, 2025 | FDA | |
| Alcon Laboratories, Inc. | PMA supplement | Feb 11, 2026 | FDA | |
| Alcon Laboratories, Inc. | PMA supplement | Mar 2, 2026 | FDA | |
| Alcon Laboratories, Inc. | PMA supplement | Jul 2, 2026 | FDA | |
Acrosof Posterior Chamber Intraocular LensP930014/S163 | Alcon Laboratories, Inc. | PMA supplement | Jul 6, 2026 | FDA |
| Alcon Laboratories, Inc. | PMA supplement | Jul 8, 2026 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Laboratories, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6201 S. Fwy. Dr., Fort Worth, TX, 76134
Sources and methodology
- Original FDA record: P930014/S161
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






